We could not find any results for:
Make sure your spelling is correct or try broadening your search.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator in... InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. Show more
Virtual R&D event to be held on June 5, 2024 from 12:00 to 2:00 PM EDT β highlighting company plans for INF904 and the opportunity, the role of C5aR in chronic spontaneous urticaria (CSU) and...
JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR...
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.26 | 21.6666666667 | 1.2 | 1.49 | 1.17 | 161440 | 1.32571232 | CS |
4 | 0.19 | 14.9606299213 | 1.27 | 1.49 | 1.165 | 163330 | 1.31631473 | CS |
12 | -0.01 | -0.680272108844 | 1.47 | 1.92 | 1.165 | 222852 | 1.51281725 | CS |
26 | -0.01 | -0.680272108844 | 1.47 | 2.11 | 1.165 | 237833 | 1.55874882 | CS |
52 | -3.44 | -70.2040816327 | 4.9 | 4.92 | 1.14 | 259216 | 2.29067754 | CS |
156 | -1.36 | -48.2269503546 | 2.82 | 7.2499 | 0.7762 | 663028 | 3.90967957 | CS |
260 | -40.15 | -96.4912280702 | 41.61 | 42.99 | 0.7762 | 706528 | 4.17683459 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions